Who can use VOXZOGO(Vosoritide)?

VOXZOGO (vosoritide) is specifically indicated for pediatric patients with achondroplasia who have open epiphyses (open bone growth plates). 

Who Can Use VOXZOGO (Vosoritide)?

Its primary use is to increase linear growth in this population.

Age: The drug is approved for use in children from age 5 years to adolescents (the study included patients aged 4.4 months to 15 years).

Essential Requirement: Patients must have open epiphyses confirmed by a healthcare provider. Treatment must be permanently discontinued once growth plates close.

Key Restriction: VOXZOGO is not recommended for patients with significant renal impairment (eGFR < 60 mL/min/1.73 m²).

Patients must also be able to follow administration requirements, including adequate food/fluid intake before the daily subcutaneous injection.